REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The goal of this study is to report on the size of the global and regional markets for imaging equipment used in the diagnosis of cancer. This includes the markets of 2009 and 2010 and the trends and sales in these markets for 2010 through 2015. Important manufacturers, technologies and factors influencing demand are discussed, including reasons behind the market forecasts, drivers and restraints in each market segment, and current and expected environmental influences on these markets.
The reader of this study will gain a solid overall look at the current market for diagnostic imaging equipment in oncology, and the elements expected to drive the markets during the next 5 years. The reader will be better equipped to create a company strategy that will positively affect business activities and revenue during the next 5 years.
REASONS FOR DOING THE STUDY
Developments in diagnostic imaging are radically changing oncology diagnostic procedures. Due to the breadth and scope of these developments, there are significant opportunities for companies to both design and market new products, and to profitably partner with companies offering complementary equipment. This study discusses where such opportunities lie today, and in what directions future prospects may lie.
SCOPE OF REPORT
Oncology diagnostic imaging products designate hardware, software, and supplies used to create, view, and manage visual images of nonvisible organs of the human body for purposes of diagnosing cancer. The report focuses on end-user markets, including hospitals, freestanding clinics, doctors’ offices, and equipment leasing companies.
The following well-established technologies are included in the study: flat panel display (FPD) products such as computed radiography (CR), x-ray, including analog and digital x-ray; magnetic resonance imaging (MRI), including standard MRI and functional MRI or MR fluoroscopy; computed tomography (CT), including standard CT, multislice or ultrafast CT, and electron beam tomography; single photon emission computed tomography (SPECT); positron emission tomography (PET); ultrasound; and endoscopy, including fiber-optic endoscopy, video endoscopy, and ingestible cameras. In the last few years, several multimodal products have been developed in an attempt to combine the advantages of structural and functional imaging. Multimodal combinations currently on the market include CT/SPECT; PET/CT; MRI/MSI; and endoscopic ultrasound (EUS), combining fiber-optic endoscopy and ultrasound. Nearly 100% of all PET sales today are in the form of combination PET/CT imaging systems; therefore, this report addresses the market for PET/CT oncology diagnostics systems rather than PET standalone systems.
New and emerging technologies that may become commercially significant by 2015 are also addressed in this report. These include contrast-enhanced ultrasound, subharmonic breast ultrasound, whole-breast ultrasound tomography, radiation luminescence and radioactive optical nano-imaging techniques, near-infrared fluorescent imaging, near-infrared (NIR) optical coherence tomography, supersonic shear imaging (SSI), microwave tomography, cone beam CT, digital breast tomosynthesis (DBT), single-shot spectral imaging (SSSI) for mammography, breast-specific gamma imaging (BSGI), and photoacoustic tomography (PT). The latest development in combination imaging is PET/MR, now being introduced by Siemens, Philips, and GE.
Products used for radiotherapy, dentistry, nonmedical imaging (e.g., in physics, chemistry, geology, and industry), and veterinary medicine are excluded from the study.
INTENDED AUDIENCE
This report is intended for industry managers of business development, marketing and engineering; CEOs; venture capital companies; and research and development companies and executives.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research methodologies were used in preparing this report. Information was acquired from interviews with industry managers and physicians. Information also came from extensive secondary research in medical journals, newsletters, manufacturers’ websites, published news items, and research reports on the Internet.
ANALYST CREDENTIALS
The analyst has an undergraduate degree in biology and graduate degrees in business administration and master’s of science in business. In addition, the analyst has over a decade of experience in marketing, market research, and business development in medical devices, diagnostics, and pharmaceuticals in the U.S. and Europe.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place
- direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers.
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The authors assume no responsibility for any loss or damage that might result from reliance on the reported information or its use.
